

# David S H Bell Mb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3849234/publications.pdf>

Version: 2024-02-01

74  
papers

4,082  
citations

346980

22  
h-index

129628

63  
g-index

75  
all docs

75  
docs citations

75  
times ranked

5935  
citing authors

#	ARTICLE	IF	CITATIONS
1	Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient. <i>Diabetes Therapy</i> , 2022, , 1.	1.2	0
2	Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1423-1428.	2.2	22
3	Diabetogenic effects of cardioprotective drugs. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 877-885.	2.2	13
4	Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy. <i>Diabetes Therapy</i> , 2021, 12, 2795-2799.	1.2	5
5	Alcohol Consumption as a Causator and/or an Accelerator of Neuropathy in People With Diabetes Is Regularly Overlooked. <i>Diabetes Therapy</i> , 2021, 12, 2631-2634.	1.2	2
6	Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?. <i>Diabetes Therapy</i> , 2021, 12, 3025-3035.	1.2	9
7	Why Do Falls and Lower Limb Fractures Occur More Frequently in the Diabetic Patient and How Can They Be Prevented?. <i>Diabetes Therapy</i> , 2020, 11, 1687-1694.	1.2	6
8	Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108199.	1.1	5
9	Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin. <i>Diabetes Therapy</i> , 2020, 11, 1175-1177.	1.2	0
10	Stroke in the patient with diabetes (part 1) – Epidemiology, etiology, therapy and prognosis. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108193.	1.1	14
11	Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 210-217.	2.2	95
12	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1277-1290.	2.2	64
13	Correlation between serum uric acid and diabetic peripheral neuropathy – association rather than causation. <i>Journal of the Neurological Sciences</i> , 2018, 390, 208.	0.3	2
14	Finally, after 56 years of type 1 diabetes: a regimen that works. <i>Postgraduate Medicine</i> , 2018, 130, 409-410.	0.9	2
15	Re: Diabetic Ketoacidosis in Patients with Type 2 Diabetes On Sglt-2 Inhibitors: an Ongoing Concern. <i>Endocrine Practice</i> , 2018, 24, 126.	1.1	2
16	Should we still be utilizing warfarin in the type 2 diabetic patient?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2327-2329.	2.2	4
17	Increase in glycated haemoglobin concentrations after unwarranted prescription changes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2510-2511.	2.2	2
18	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: sequential or simultaneous start?. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 909-911.	2.2	12

#	ARTICLE	IF	CITATIONS
19	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. <i>Endocrine Practice</i> , 2017, 23, 1-87.	1.1	766
20	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 422-434.	1.6	87
21	Aspirin in the prevention of cardiovascular events in patients with diabetes. <i>Postgraduate Medicine</i> , 2016, 128, 180-190.	0.9	5
22	Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient. <i>Case Reports in Endocrinology</i> , 2015, 2015, 1-4.	0.2	7
23	Reply. <i>American Journal of Cardiology</i> , 2015, 115, 852-853.	0.7	0
24	Riceabetes: is the association of type 2 diabetes with rice intake due to a high carbohydrate intake or due to exposure to excess inorganic arsenic?. <i>Postgraduate Medicine</i> , 2015, 127, 781-782.	0.9	6
25	Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR. <i>Postgraduate Medicine</i> , 2012, 124, 121-135.	0.9	8
26	Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2012, 110, 826-833.	0.7	141
27	Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 128-138.	1.4	50
28	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol and its Association With the Beneficial Impact of Pioglitazone on Coronary Atherosclerosis in the PERISCOPE Study Is Likely Due to Lowering Insulin Resistance. <i>Journal of the American College of Cardiology</i> , 2011, 58, 778.	1.2	4
29	Protean Manifestations of Vitamin D Deficiency, Part 3. <i>Southern Medical Journal</i> , 2011, 104, 340-344.	0.3	9
30	Protean Manifestations of Vitamin D Deficiency, Part 1. <i>Southern Medical Journal</i> , 2011, 104, 331-334.	0.3	15
31	Metformin-Induced Vitamin B12 Deficiency Presenting as a Peripheral Neuropathy. <i>Southern Medical Journal</i> , 2010, 103, 265-267.	0.3	95
32	Resolution of Statin-Induced Myalgias by Correcting Vitamin D Deficiency. <i>Southern Medical Journal</i> , 2010, 103, 690-692.	0.3	31
33	The Association of Obesity, Metabolic Syndrome, Diabetes, and Cardiovascular Disease with Nonalcoholic Fatty Liver Disease. <i>Southern Medical Journal</i> , 2009, 102, 991-992.	0.3	5
34	Metabolic syndrome and postoperative atrial fibrillation (POAF). <i>European Heart Journal</i> , 2009, 30, 1167-1168.	1.0	4
35	Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. <i>Acta Diabetologica</i> , 2009, 46, 155-155.	1.2	0
36	Treatment of diabetic hypertension. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 433-444.	2.2	16

#	ARTICLE	IF	CITATIONS
37	Successful Utilization of Aliskiren, a Direct Renin Inhibitor in Bartter Syndrome. Southern Medical Journal, 2009, 102, 413-415.	0.3	2
38	Importance of Postprandial Glucose Levels in Type 2 Diabetes. Southern Medical Journal, 2009, 102, 553.	0.3	1
39	Hypertension and Diabetes—A Toxic Combination. Endocrine Practice, 2008, 14, 1031-1039.	1.1	21
40	Peyronie Disease in Association with Carvedilol: A Case Report. Southern Medical Journal, 2008, 101, 1157-1158.	0.3	5
41	Diabetes: A Cardiac Condition Manifesting as Hyperglycemia. Endocrine Practice, 2008, 14, 924-932.	1.1	19
42	Postprandial Dysmetabolism: the Missing Link Between Diabetes and Cardiovascular Events?. Endocrine Practice, 2008, 14, 112-124.	1.1	72
43	Triple oral therapy for type 2 diabetes. Diabetes Research and Clinical Practice, 2007, 78, 313-315.	1.1	8
44	Insulin Therapy in Diabetes Mellitus. Drugs, 2007, 67, 1813-1827.	4.9	20
45	Heart Failure in the Diabetic Patient. Cardiology Clinics, 2007, 25, 523-538.	0.9	13
46	Postprandial Hyperglycemia/Hyperlipidemia (Postprandial Dysmetabolism) Is a Cardiovascular Risk Factor. American Journal of Cardiology, 2007, 100, 899-904.	0.7	452
47	The Case for Combination Therapy as First-Line Treatment for the Type 2 Diabetic Patient. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 131-137.	1.8	10
48	The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Current Medical Research and Opinion, 2006, 22, 287-296.	0.9	66
49	Treatment of type 2 diabetes. Postgraduate Medicine, 2006, 119, 15-20.	0.9	1
50	Treatment of type 2 diabetes. Postgraduate Medicine, 2006, 119, 8-14.	0.9	4
51	Do sulfonylurea drugs increase the risk of cardiac events?. Cmaj, 2006, 174, 185-186.	0.9	54
52	Strategies to prevent type 2 diabetes. Current Medical Research and Opinion, 2005, 21, 1107-1114.	0.9	40
53	Differential Effects of $\beta$ -Blockers on Albuminuria in Patients With Type 2 Diabetes. Hypertension, 2005, 46, 1309-1315.	1.3	76
54	Insulin as Initial Therapy for Type 2 Diabetes is Not in the Patient's Best Interest. Endocrine Practice, 2004, 10, 208-212.	1.1	5

#	ARTICLE	IF	CITATIONS
55	Effect of Rosiglitazone Versus Insulin on the Pancreatic $\beta$ -Cell Function of Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 2585-2589.	4.3	87
56	Efficacy of Conversion From Bedtime NPH Insulin Injection to Once- or Twice-Daily Injections of Insulin Glargine in Type 1 Diabetic Patients Using Basal/Bolus Therapy. <i>Diabetes Care</i> , 2004, 27, 632-633.	4.3	75
57	Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2227.	3.8	710
58	Management of Type 2 Diabetes With Thiazolidinediones. , 2004, 14, 293-299.		7
59	The Role of C-Peptide Levels in Screening for Latent Autoimmune Diabetes in Adults. <i>American Journal of Therapeutics</i> , 2004, 11, 308-311.	0.5	23
60	Advances in diabetes for the millennium: the heart and diabetes. <i>MedGenMed: Medscape General Medicine</i> , 2004, 6, 7.	0.2	0
61	$\beta$ -Cell rejuvenation with thiazolidinediones. <i>American Journal of Medicine</i> , 2003, 115, 20-23.	0.6	60
62	Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. <i>Diabetes Care</i> , 2003, 26, 2433-2441.	4.3	387
63	Use of Beta Blockers in the Patient With Diabetes. , 2003, 13, 116-123.		17
64	Why I Initiate Therapy with Two Insulin Sensitizers in Patients with Type 2 Diabetes. <i>Endocrine Practice</i> , 2003, 9, 98-100.	1.1	9
65	Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2003, Spec No, 35-44.	0.9	3
66	Long-Term Efficacy of Triple Oral Therapy for Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2002, 8, 271-275.	1.1	50
67	Current status of diabetes treatment. <i>Southern Medical Journal</i> , 2002, 95, 24-9.	0.3	3
68	Chronic complications of diabetes. <i>Southern Medical Journal</i> , 2002, 95, 30-4.	0.3	1
69	Drugs for cardiovascular risk reduction in the diabetic patient. <i>Current Diabetes Reports</i> , 2001, 1, 133-139.	1.7	5
70	Dealing with diabetic nephropathy. <i>Postgraduate Medicine</i> , 1999, 105, 83-94.	0.9	10
71	Diabetic ketoacidosis. <i>Postgraduate Medicine</i> , 1997, 101, 193-204.	0.9	15
72	Lower limb problems in diabetic patients. <i>Postgraduate Medicine</i> , 1991, 89, 237-244.	0.9	8

#	ARTICLE	IF	CITATIONS
73	Dosage Accuracy of Self-mixed vs Premixed Insulin. Archives of Internal Medicine, 1991, 151, 2265.	4.3	32
74	Peripheral and autonomic syndromes. Postgraduate Medicine, 1982, 71, 50-67.	0.9	19